Factors influencing serum concentrations of levetiracetam in dogs with epilepsy
Journal of Veterinary Internal Medicine · 2024
DOI: 10.1111/jvim.17128 ↗At a glance
Journal article in Journal of Veterinary Internal Medicine, 2024. Written by Marine Saint-Maxent and 4 co-authors. Institution: Département de Sciences Cliniques, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, Quebec, Canada. Major MEDLINE topics: Levetiracetam, Dog Diseases, Anticonvulsants, Epilepsy. 20 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Natural Sciences and Engineering Research Council of Canada.
Abstract (original language)
Background
Factors affecting serum concentrations of levetiracetam in dogs are unknown and could affect the efficacy of levetiracetam in controlling seizures in dogs with epilepsy. Hypothesis/Objectives Higher PO doses of levetiracetam will be needed in dogs to achieve serum concentrations shown to be effective in humans. Determine factors that could influence serum levetiracetam concentrations and justify dose adjustment in some epileptic dogs. Animals Sixty-nine client-owned dogs with epilepsy treated with levetiracetam alone or in combination, based on 127 trough serum concentration measurements of levetiracetam.
Methods
Retrospective cohort study. Linear mixed models were used to assess the effect of patient signalment and concurrent drug administration on serum concentrations of levetiracetam and the effect of serum concentration of levetiracetam on seizure frequency reduction.
Results
The PO dose of levetiracetam significantly explained changes in serum levetiracetam concentration, and this causal link was stronger with monotherapy (R2 = 0.59, P < .001). Phenobarbital significantly decreased serum levetiracetam concentration in a dose dependent manner (R2 = 0.30, P = .003). Based on our model, a levetiracetam dosage of 99–216 mg/kg/day is necessary to obtain a serum levetiracetam concentration of 20 μg/mL when used alone or concurrently with 7 mg/kg/day of phenobarbital. No other factors were found to influence serum levetiracetam concentrations. No therapeutic range could be identified. Conclusion and Clinical Importance Our data suggest that a dosage of 99–216 mg/kg/day of levetiracetam is needed to achieve a serum concentration known to be therapeutically effective in humans, especially when administered concomitantly with phenobarbital.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Département de Sciences Cliniques, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, Quebec, Canada.
- Vice-décanat à la Recherche, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, Quebec, Canada.
- Centre Interdisciplinaire de Recherche sur le Cerveau et L'apprentissage (CIRCA), Université de Montréal, Montreal, Quebec, Canada.
ORCID profiles: Tristan Juette, Thomas Parmentier
Funding
- Natural Sciences and Engineering Research Council of Canada
Cite
APA
Saint-Maxent, M., Juette, T., Parent, J., Castel, A., & Parmentier, T. (2024). Factors influencing serum concentrations of levetiracetam in dogs with epilepsy. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.17128
Vancouver
Saint-Maxent M, Juette T, Parent J, Castel A, Parmentier T. Factors influencing serum concentrations of levetiracetam in dogs with epilepsy. Journal of Veterinary Internal Medicine. 2024. doi:10.1111/jvim.17128
BibTeX
@article{SaintMaxent2024,
author = {Saint-Maxent, Marine and Juette, Tristan and Parent, Joane and Castel, Aude and Parmentier, Thomas},
title = {Factors influencing serum concentrations of levetiracetam in dogs with epilepsy},
journal = {Journal of Veterinary Internal Medicine},
year = {2024},
doi = {10.1111/jvim.17128}
}
EUVIMED